Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Multiple Sclerosis and Pregnancy: Current Considerations.
Forward Pharma Receives Decision to Grant From EPO for DMF Patent in Europe
Complex antibody profiling to predict clinical outcome in childhood ADS.
The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria.
Thrombotic microangiopathy associated with use of interferon-beta.
Treatment of progressive multiple sclerosis: what works, what does not, and what is needed.
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.
Nephrotic Syndrome in a Multiple Sclerosis Patient Receiving Long-term Interferon Beta Therapy.
Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
Genzyme’s LEMTRADA™ (alemtuzumab) application for MS accepted for review by the FDA
Zebrafish myelination: a transparent model for remyelination?
Rituximab product approval information - Licensing action
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
Mechanism-based CNS Disease Modeling: Applications in Neurology and Psychiatry Drug Research & Development
Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
Interferon β for secondary progressive multiple sclerosis: a systematic review.
Glatiramer acetate ameliorates inflammatory bowel disease in mice through the induction of Qa-1-restricted CD8⁺ regulatory cells.
Effect of Glatiramer Acetate on Peripheral Blood Brain-Derived Neurotrophic Factor and Phosphorylated TrkB Levels in Relapsing-Remitting Multiple Sclerosis.
Integrated genomic and prospective clinical studies show the importance of modular pleiotropy for disease susceptibility, diagnosis and treatment.
Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.
Immunological mechanisms underlying delayed-type hypersensitivity reactions to glatiramer acetate.
Inflammation-induced fatigue: Exploring neurobiological mechanisms and potential treatments

Pages